Exact Sciences (EXAS) PT Trimmed to $130 at Cowen; Named Best 2020 Idea

Cowen analyst Doug Schenkel lowered the price target on Exact Sciences (NASDAQ: EXAS) to $130.00 (from $135.00) while maintaining an Outperform rating. The analyst named the stock a Best Idea for 2020.

The analyst commented, "EXAS remains our favorite large-cap, growth stock pick. We see a path to ~50% upside from current levels over the NTM. We expect robust Cologuard growth that exceeds Street expectations, are increasingly positive on how much GHDX can help EXAS commercially and operationally, believe the product pipeline is under-appreciated, and feel concerns are disproportionally captured in current valuation."

You May Also Be Interested In

• Berenberg Upgrades Accelleron Industries AG (ACLN:SW) to Buy
• Raymond James Downgrades Accelerant Holdings (ARX) to Market Perform
• Nomura/Instinet Downgrades Indraprastha Gas Ltd. (IGL:IN) to Neutral